Skip to main content
main-content

08-06-2021 | ASCO 2021 | Conference coverage | Video

Trial of TAK-700 in metastatic HSPC fails to meet primary endpoint

Neeraj Agarwal explains why the results of the phase 3 SWOG S1216 trial of androgen deprivation therapy plus the 17,20-lyase inhibitor TAK-700 herald good news for men with metastatic hormone-sensitive prostate cancer despite the study not meeting its primary endpoint (5:08).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits